Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor–Positive Breast Cancer

Purpose: CDK-activating kinase (CAK) is required for the regulation of the cell cycle and is a trimeric complex consisting of cyclin-dependent kinase 7 (CDK7), Cyclin H, and the accessory protein, MAT1. CDK7 also plays a critical role in regulating transcription, primarily by phosphorylating RNA polymerase II, as well as transcription factors such as estrogen receptor-α (ER). Deregulation of cell cycle and transcriptional control are general features of tumor cells, highlighting the potential for the use of CDK7 inhibitors as novel cancer therapeutics. Experimental Design: mRNA and protein expression of CDK7 and its essential cofactors cyclin H and MAT1 were evaluated in breast cancer samples to determine if their levels are altered in cancer. Immunohistochemical staining of >900 breast cancers was used to determine the association with clinicopathologic features and patient outcome. Results: We show that expressions of CDK7, cyclin H, and MAT1 are all closely linked at the mRNA and protein level, and their expression is elevated in breast cancer compared with the normal breast tissue. Intriguingly, CDK7 expression was inversely proportional to tumor grade and size, and outcome analysis showed an association between CAK levels and better outcome. Moreover, CDK7 expression was positively associated with ER expression and in particular with phosphorylation of ER at serine 118, a site important for ER transcriptional activity. Conclusions: Expressions of components of the CAK complex, CDK7, MAT1, and Cyclin H are elevated in breast cancer and correlate with ER. Like ER, CDK7 expression is inversely proportional to poor prognostic factors and survival. Clin Cancer Res; 22(23); 5929–38. ©2016 AACR.

[1]  C. Caldas,et al.  Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer , 2015, Oncotarget.

[2]  I. Ellis,et al.  Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer , 2015, Breast Cancer Research and Treatment.

[3]  Marion Peyressatre,et al.  Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors , 2015, Cancers.

[4]  Xin Huang,et al.  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.

[5]  D. Heitjan,et al.  CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment , 2014, Clinical Cancer Research.

[6]  Yan Liu,et al.  Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. , 2014, Cancer cell.

[7]  Bandana Sharma,et al.  CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer , 2014, Cell.

[8]  Sridhar Ramaswamy,et al.  Targeting transcription regulation in cancer with a covalent CDK7 inhibitor , 2014, Nature.

[9]  I. Ellis,et al.  Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer , 2014, Breast Cancer Research and Treatment.

[10]  D. Rimm,et al.  Pin1 modulates ERα levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation , 2014, Oncogene.

[11]  Stephen P. Fox,et al.  Co-regulated gene expression by oestrogen receptor α and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cells , 2013, Nucleic acids research.

[12]  Chun Cheng,et al.  Low Expression of CyclinH and Cyclin-Dependent Kinase 7 Can Decrease the Proliferation of Human Esophageal Squamous Cell Carcinoma , 2013, Digestive Diseases and Sciences.

[13]  M. Barbacid,et al.  Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion , 2012, The EMBO journal.

[14]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[15]  Karl A. Merrick,et al.  Why minimal is not optimal: Driving the mammalian cell cycle—and drug discovery—with a physiologic CDK control network , 2012, Cell cycle.

[16]  I. Ellis,et al.  Differential oestrogen receptor binding is associated with clinical outcome in breast cancer , 2011, Nature.

[17]  J. Egly,et al.  The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin/proteasome process , 2011, The EMBO journal.

[18]  L. Murphy,et al.  Clinical significance of estrogen receptor phosphorylation. , 2011, Endocrine-related cancer.

[19]  A. Thompson,et al.  Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study , 2010, British Journal of Cancer.

[20]  J. Snyder,et al.  The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. , 2009, Cancer research.

[21]  Li Jia,et al.  Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. , 2009, Cancer research.

[22]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[23]  B. Ramaswamy,et al.  Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with hormone responsive advanced breast cancer: no evidence of a pharmacokinetic interaction between exemestane and fulvestrant. , 2009 .

[24]  G. Ball,et al.  Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. , 2008, European journal of cancer.

[25]  Jérôme Eeckhoute,et al.  Positive Cross-Regulatory Loop Ties GATA-3 to Estrogen Receptor α Expression in Breast Cancer , 2007 .

[26]  C. R. Wilson,et al.  Ménage-à-Trois 1 Is Critical for the Transcriptional Function of PPARγ Coactivator 1 , 2007 .

[27]  J. Eeckhoute,et al.  Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. , 2007, Cancer research.

[28]  Simak Ali,et al.  Phosphorylation of ERα at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERα phosphorylation in breast cancer progression , 2006 .

[29]  G. Shapiro,et al.  Cyclin-dependent kinase pathways as targets for cancer treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Shousha,et al.  Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. , 2006, Endocrine-related cancer.

[31]  R. Fisher Secrets of a double agent: CDK7 in cell-cycle control and transcription , 2005, Journal of Cell Science.

[32]  M. Barbacid,et al.  Mammalian cyclin-dependent kinases. , 2005, Trends in biochemical sciences.

[33]  G. Ball,et al.  High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.

[34]  R. Métivier,et al.  Differential Regulation of Estrogen-Inducible Proteolysis and Transcription by the Estrogen Receptor α N Terminus , 2005, Molecular and Cellular Biology.

[35]  T. Barrette,et al.  Mining for regulatory programs in the cancer transcriptome , 2005, Nature Genetics.

[36]  L. Johnson,et al.  CAK—Cyclin-Dependent Activating Kinase: A Key Kinase in Cell Cycle Control and a Target for Drugs? , 2005, Cell cycle.

[37]  G Leclercq,et al.  About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-α gene (ESR1) in breast cancer , 2004, Molecular and Cellular Endocrinology.

[38]  Simak Ali,et al.  Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera , 2002, Oncogene.

[39]  M. Barbacid,et al.  To cycle or not to cycle: a critical decision in cancer , 2001, Nature reviews. Cancer.

[40]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[41]  Gregor Mikuz,et al.  Ep-CAM overexpression in breast cancer as a predictor of survival , 2000, The Lancet.

[42]  P. Chambon,et al.  TFIIH Interacts with the Retinoic Acid Receptor γ and Phosphorylates Its AF-1-activating Domain through cdk7* , 2000, The Journal of Biological Chemistry.

[43]  Simak Ali,et al.  Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. , 2000, Molecular cell.

[44]  Chawnshang Chang,et al.  From Androgen Receptor to the General Transcription Factor TFIIH , 2000, The Journal of Biological Chemistry.

[45]  A. Levine,et al.  The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro , 1997, Molecular and cellular biology.

[46]  P. Chambon,et al.  Stimulation of RARα Activation Function AF-1 through Binding to the General Transcription Factor TFIIH and Phosphorylation by CDK7 , 1997, Cell.

[47]  J. Bartek,et al.  Expression of CDK7/CAK in normal and tumour cells of diverse histogenesis, cell‐cycle position and differentiation , 1996, International journal of cancer.